New Clinical Trial Confirms DermaTherapy® Reduces Number of Pressure Injuries in Intensive Care Units
Published: Mar 13, 2018
CINCINNATI, March 13, 2018 /PRNewswire/ -- Standard Textile and Precision Fabrics Group announce results from a clinical trial evaluating DermaTherapy® technology, published in the November 2017 issue of the American Journal of Critical Care. Authors of the study from Michigan Medicine, the academic medical center of the University of Michigan, concluded: "The use of specialty linens in addition to standard techniques for preventing pressure injuries can help prevent pressure injuries from developing in high-risk patients in intensive care units." (American Journal of Critical Care. 2017; 26: 474-481)
DermaTherapy® is the first and only silk-like therapeutic bedding linens to receive FDA 510(k)1 clearance as a Class I medical device that helps to reduce the likelihood of patients developing pressure injuries. Nearly 4,000 patients were included in the evaluation of DermaTherapy® on the rate of pressure injuries (PIs) in high-risk patients in the cardiovascular and surgical intensive care units at the University of Michigan hospital in Ann Arbor, Michigan.
According to the study, the 46% reduction of posterior PIs led to a potential cost savings for the health system of nearly $4 million. The article states that "cost savings more than covered the increased cost of the specialty linens." In addition, Michigan Medicine's laundry manager, Rolando Croocks, indicated in the article that the specialty linens have withstood "repeated use and laundering for 3 times longer than cotton linens."
In the study, the researchers state: "Overall, we noted significant reductions in posterior PIs, supporting the theory that addressing microclimate can help reduce the occurrence of PIs." DermaTherapy® therapeutic bedding addresses the patient's microclimate by reducing shear and friction, and controlling moisture and heat.
With two U.S. patents (US 7,816,288 and US 8,283,267) and two pending patents, the DermaTherapy® system is comprised of a pillowcase, top flat sheet, bottom fitted sheet and underpad, all developed in partnership between Standard Textile Co., Inc. and Precision Fabrics Group. DermaTherapy® is a registered trademark of Precision Fabrics Group, Inc.
DermaTherapy® also has FDA clearance2 for use in the treatment of atopic dermatitis by patients who are susceptible to or may have mild atopic dermatitis, the most common form of eczema.
For more information, visit DermaTherapy.StandardTextile.com.
1 FDA 510(K) Clearance No. K152884. Indications for Use: Bed linens made with DermaTherapy® fabrics are intended for use by patients 18 years of age and older in hospital settings who are susceptible to pressure ulcers. The DermaTherapy® Bed Linens help to reduce the likelihood of patients developing pressure ulcers by reducing moisture, friction and shear on the patient's skin.
2 FDA 510(K) Clearance No. K061242. Indications for Use: Institutional Bedding (bed sheets and pillow cases) made with DermaTherapy® fabrics is intended for use by patients in a hospital, healthcare or home setting who are susceptible to or may have mild atopic dermatitis.
About Standard Textile
Founded in 1940, Standard Textile has developed a culture of innovation, quality, and service. With more than 70 patents, its products are engineered to deliver durability, longevity, and value. A vertically integrated company, Standard Textile is a leading global provider of total solutions in the institutional textiles and apparel markets. Leveraging textile design, manufacturing, and laundry expertise, and its global infrastructure, this company serves customers in the healthcare, hospitality, interiors, workwear, and consumer markets worldwide. For more information visit standardtextile.com.
About Precision Fabrics Group
"Innovation" is a designation that must be earned. It happens when new ground is broken; when pioneering products set new standards. At Precision Fabrics, we set out to raise the bar for our industry. Today, innovation fuels our company. We're expert manufacturers of woven and nonwoven fabrics for high performance industries such as medical, aerospace, military, industrial, protective apparel, and more. But at Precision Fabrics, we do more than simply produce and supply products to a worldwide market: we solve problems with strong research and development, excellent customer service, and quality manufacturing. For more information, visit www.precisionfabrics.com.
About Michigan Medicine
At Michigan Medicine, we create the future of healthcare through the discovery of new knowledge for the benefit of patients and society; educate the next generation of physicians, health professionals and scientists; and serve health needs throughout the state of Michigan and beyond. We pursue excellence every day in our three hospitals, 40 outpatient locations and home care operations that handle more than 2.1 million outpatient visits a year. The U-M Medical School is one of the nation's biomedical research powerhouses, with total research funding of more than $470 million.
Vice President, Brand Marketing and Communications, Standard Textile
View original content with multimedia: http://www.prnewswire.com/news-releases/new-clinical-trial-confirms-dermatherapy-reduces-number-of-pressure-injuries-in-intensive-care-units-300612597.html
SOURCE Standard Textile